Cargando…
Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment
A 45-year-old Italian woman, affected by relapsing–remitting multiple sclerosis (RR-MS) starting from 2011, started treatment with alemtuzumab in July 2016. Nine months after the second infusion, she had an immune thrombocytopenic purpura (ITP) with complete recovery after steroid treatment. Three m...
Autores principales: | Buscarinu, Maria Chiara, Fornasiero, Arianna, Pellicciari, Giulia, Reniè, Roberta, Landi, Anna Chiara, Bozzao, Alessandro, Cappelletti, Cristina, Bernasconi, Pia, Ristori, Giovanni, Salvetti, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895826/ https://www.ncbi.nlm.nih.gov/pubmed/31671619 http://dx.doi.org/10.3390/brainsci9110299 |
Ejemplares similares
-
The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology
por: Buscarinu, Maria Chiara, et al.
Publicado: (2019) -
Two Unique Cases with Anti-GluR Antibody-Positive Encephalitis
por: Matsuzono, Kosuke, et al.
Publicado: (2013) -
Late-Onset MS: Disease Course and Safety-Efficacy of DMTS
por: Buscarinu, Maria Chiara, et al.
Publicado: (2022) -
GluR2(Q) and GluR2(R) AMPA Subunits are not Targets of lypd2 Interaction
por: Lauriello, Anna, et al.
Publicado: (2022) -
MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases
por: Mechelli, Rosella, et al.
Publicado: (2021)